3.48
-0.01 (-0.29%)
| Previous Close | 3.49 |
| Open | 3.54 |
| Volume | 690,325 |
| Avg. Volume (3M) | 1,135,188 |
| Market Cap | 322,502,400 |
| Price / Book | 2.16 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -2.30 |
| Total Debt/Equity (MRQ) | 20.81% |
| Current Ratio (MRQ) | 5.92 |
| Operating Cash Flow (TTM) | -119.19 M |
| Levered Free Cash Flow (TTM) | -66.77 M |
| Return on Assets (TTM) | -40.11% |
| Return on Equity (TTM) | -81.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Bearish | Mixed |
| Medical Care Facilities (Global) | Bearish | Mixed | |
| Stock | COMPASS Pathways Plc - American | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -2.5 |
| Average | -0.38 |
|
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| % Held by Insiders | 14.08% |
| % Held by Institutions | 43.05% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (HC Wainwright & Co., 1,193.10%) | Buy |
| Median | 16.50 (374.14%) | |
| Low | 11.00 (Stifel, 216.09%) | Buy |
| Average | 22.25 (539.37%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 3.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2025 | 45.00 (1,193.10%) | Buy | 3.85 |
| 13 Feb 2025 | 40.00 (1,049.43%) | Buy | 4.42 | |
| Canaccord Genuity | 28 Feb 2025 | 15.00 (331.03%) | Buy | 3.93 |
| Stifel | 27 Feb 2025 | 11.00 (216.09%) | Buy | 3.92 |
| RBC Capital | 15 Jan 2025 | 18.00 (417.24%) | Buy | 3.45 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Mar 2025 | Announcement | Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression |
| 11 Mar 2025 | Announcement | Compass Pathways to Participate in Stifel Virtual CNS Forum |
| 27 Feb 2025 | Announcement | Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights |
| 25 Feb 2025 | Announcement | Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference |
| 18 Feb 2025 | Announcement | Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025 |
| 05 Feb 2025 | Announcement | Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference |
| 21 Jan 2025 | Announcement | Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer |
| 10 Jan 2025 | Announcement | Compass Pathways Announces Pricing of Underwritten Offering |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |